FDA Warning Letter · #737810
Cheap Medicine Shop — FDA Warning Letter (September 24, 2026)
Cheap Medicine Shop received this warning letter on September 24, 2026, from FDA’s Center for Drug Evaluation and Research (CDER). What it cites, and FDA’s own words where we matched them against the letter, are summarized below.
Primary Source
View the original FDA letter on fda.gov →
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cheap-medicine-shopwwwcheapmedicineshopcom-737810-09242026
Summary
- Company
- Cheap Medicine Shop
- Letter number
- #737810
- Issue date
- September 24, 2026
- Subject
- Unapproved New Drugs/Misbranded (Internet Pharmacy)
What FDA cited
FDA's letter of September 24, 2026 cites Cheap Medicine Shop for selling products FDA calls unapproved new drugs, under the subject line "Unapproved New Drugs/Misbranded (Internet Pharmacy)". The GLP-1 drugs it names: semaglutide.
As discussed below, FDA has observed that www.cheapmedicineshop.com introduces into interstate commerce unapproved and misbranded injectable semaglutide drug products.
How this letter sits against the other 158
Our reading, from the 159 letters on this register — not part of the FDA’s document.
No other letter on this register carries the date September 24, 2026. The agency acted against this company on its own that day, which is uncommon here — most of the letters we hold arrived in sweeps.
A warning letter is the agency putting a company on notice, not a court finding and not a ban. What it is worth to you is in what it alleges, so read the original on fda.gov rather than the fact that one exists.
From the letter
Read full letter on FDA.gov →Word for word, from the letter of September 24, 2026
This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website www.cheapmedicineshop.com. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that you comply with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.
As discussed below, FDA has observed that www.cheapmedicineshop.com introduces into interstate commerce unapproved and misbranded injectable semaglutide drug products. There are inherent risks to consumers who purchase unapproved and misbranded drug products. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body's natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis.
Accordingly, FDA requests that www.cheapmedicineshop.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm.
Violations were identified and documented during a review of your website www.cheapmedicineshop.com, FDA Establishment Identifier (FEI) 3041109073, on August 26, 2026, and September 2, 2026.
On your website at internet address www.cheapmedicineshop.com, you introduce into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), 301(d), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 331(a), 331(d), 352(f)(1), 353(b)(1), and 355(a)).
The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.
Certain products offered for sale by www.cheapmedicineshop.com are drugs within the meaning of section 201(g) of the FD&C Act (21 U.S.C. 321(g)) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body. These drugs are also new drugs as defined by section 201(p) of the FD&C Act (21 U.S.C. 321(p)), because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act.
You failed to obtain approved applications pursuant to section 505 of the FD&C Act (21 U.S.C. 355) for these products that you have introduced into interstate commerce. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act.
Quoted word for word from the U.S. Food and Drug Administration. We assert nothing beyond what the agency published, and the full letter is at https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/cheap-medicine-shopwwwcheapmedicineshopcom-737810-09242026
What FDA warning letters mean
It is the agency writing to a company to say it believes something that company is doing breaks the Federal Food, Drug, and Cosmetic Act — usually a claim on a website, a labeling choice, or how a drug is being made. The company has about fifteen working days to write back.
Read carefully what it is not. It is not a recall, not a criminal charge, and not a court deciding anyone broke the law. It is the regulator opening a file. Companies frequently answer a letter, fix what was cited, and carry on trading, and when FDA accepts that it can issue a close-out letter. We do not track close-outs, so the presence of a letter on this page tells you what FDA said on one date — not where the matter stands today. Ask the company; they will usually tell you, and how they answer is informative in itself.
Across this market the same three citations recur: claiming a compounded product is equivalent to an approved one, labeling that misleads, and compounding from bulk substances FDA has not cleared under sections 503A and 503B. If you are reading a letter here, it is probably one of those.
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Sesame Care
Oral orforglipron alongside the injectables
From $149/mo + care fee
Get started →Enhance MD
Knowing which pharmacy fills the vial: it names Tru Meds Rx
From $169/mo, prepaid
Get started →DudeMeds
Compounded semaglutide at $175/month, prepaid as a 3-month kit
From $175/mo, prepaid
Get started →Other warning letters in our database
- Online Generic Medicine — September 23, 2026
- Empower Pharmacy — September 18, 2026
- Peak Performance Peptides — August 24, 2026
- Royal Peptides LLC — August 24, 2026
- NuScience Peptides LLC — August 24, 2026
Editorial Disclaimer
This is a public communication from a regulator, and by itself it settles nothing about whether the company broke any law. Corrective action is a common response, and a fair number of letters end in a close-out. Read the whole thing on fda.gov through the link above rather than taking our excerpt as the full picture.
Glossary
The words sellers use, defined. Tap any term.
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- 503B outsourcing facility · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- FDA Warning Letter · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory